hospitalphysician Posted - 36 minutes ago

@ejz92 @Sixth_Sense I am not invested in ESPR. Their drug likely has a place, like for patients with statin intolerance. But $NAMS , even though behind , is way better. I prefer sticking to best in class.

FlynancialAnalyst Posted - 2 hours ago

$NAMS to $40 is not at all out of the question

hospitalphysician Posted - 04/30/24

@ejz92 The only worry for $NAMS is possible side effects showing up in P3 study. So far, no big issues. If side effect profile remains good, this company is waaay underpriced.

ejz92 Posted - 04/30/24

$NAMS I’m new to NAMS. From what I read this looks amazing. I didn’t see any downsides to their drug. Anything to be worried about other than the current MC is fairly high (reminds me of Viking before they took off).

donatflorida Posted - 04/30/24

$NAMS we a new member to the institutional club! Moody Aldrich Partners Llc Started a decent sized position of 111,267 at $23.65

donatflorida Posted - 04/29/24

$NAMS Bradley & Co. Private Wealth Management, Started a position of 729 shares at $23.65 There are now : 41 institutional investors holding ~ 62 million shares 6 registered insiders holding~ 26 million shares Retail holding 1.2 million shares Can you say Kaboom?

donatflorida Posted - 04/27/24

$NAMS HealthInvest Partners AB started a position of 22,394 shares with an average price $23.65. PSI Advisors, LLC Portfolio Holdings gpt in with a starter position of 500 shares at $23.65 And Dupont Capital Management Corp purchased 1 share to test out their new trading software. It works, buy more!

FlynancialAnalyst Posted - 04/26/24

A lot of these $NAMS are $BLTE different!

Jakeipedia Posted - 04/25/24

$NAMS I have to believe Michael Davidson is on a sales tour currently.

FlynancialAnalyst Posted - 04/24/24

Dont $CNTA ur chickens, or broken eggs, until u see the wkly close $XBI $NAMS $IMCR $MDGL

Jakeipedia Posted - 04/24/24

@BioRich $NAMS

Sixth_Sense Posted - 04/24/24

$NAMS like this one long term. Made initial entry here

FlynancialAnalyst Posted - 04/23/24

$NAMS $1.95B mc $XBI leader holding $20 level and showing major RS to the industry lately. 76% institutionally owned, up from 67% 2 years ago. LOW short float for a bio, just 1.14% Only 159 watchers on Stocktwits #HiddenGem cc @howardlindzon here u go! TrendEdge.app/asset/NAMS

donatflorida Posted - 04/20/24

$NAMS the Cutler Group LP sold its entire position of 500 shares in its latest 13F

donatflorida Posted - 04/18/24

$NAMS institutional update Atticus Wealth Management, Llc Sold their position.

donatflorida Posted - 04/16/24

$NAMS Institutional update: Medicxi Ventures Management (Jersey) Ltd Portfolio Holdings As reported in their 13F of April 15, Midicxi increased their shares by 50% or 150,000 shares.

donatflorida Posted - 04/12/24

$NAMS

donatflorida Posted - 04/10/24

$NAMS welcome aboard Yarbrough Capital, LLC! That's 40 institutional owners of the shares.

Hawaiianinvesta Posted - 04/09/24

$NAMS @newfguy Have a great day loser fake con job cardiologist my ass Blocking me for communicating truth that he can't handle 🖕🏽

TheTradeXchange Posted - 04/09/24

$NAMS NAMSW - NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseEnrollment to continue to the end of April to accommodate strong patient and site interest

Stock_Titan Posted - 04/09/24

$NAMS $NAMSW NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease https://www.stocktitan.net/news/NAMS/new-amsterdam-pharma-enrolls-over-9-000-patients-in-pivotal-phase-3-2aon3rv88cmg.html

donatflorida Posted - 04/08/24

$NAMS fickle hands selling ...volume very low.

newfguy Posted - 04/08/24

$NAMS so funny to have bempadoic acid ESPR cheerleaders on this board. not even in same league

Jakeipedia Posted - 04/08/24

$NAMS if this goes under 20 I might start selling my blue chips to add https://www.abstractsonline.com/pp8/#!/10973/presentation/22225

hospitalphysician Posted - 04/07/24

@donatflorida I meant to say $NAMS “efficacy/effectiveness“ is not a big risk, but typed “efficiency” instead. Sorry. Anyway , if the side effect profile stays cleans, we’re good. GL.

Hawaiianinvesta Posted - 04/07/24

@djohnson591 @Choovachok They will deal with the same thing as ESPR. When $NAMS reports their phase iii data this year, pending good results. They still won't get coverage for this drug, and or, won't see big prescriptions being written, due to the fact that insurers and prescribers need to see outcomes data. Espr suffered due to the exact same thing. Very simple really So maybe end of 2026 early 2027, that data will be out, insurers might cover it if it has good outcomes data

Choovachok Posted - 04/07/24

$ESPR New blockbaster - Obicetrapib. Obicetrapib from New Amsterdam Pharma ($NAMS) demonstrating more than 50% LDL-lowering.

hospitalphysician Posted - 04/06/24

@donatflorida Biggest risk with $NAMS is not the efficiency; it is safety. Any side major effects, like blood pressure elevations, diabetes, liver function abnormalities, and this will tank. So far, we’re looking good though.

Jakeipedia Posted - 04/05/24

$NAMS https://www.abstractsonline.com/pp8/#!/10973/presentation/22225

donatflorida Posted - 04/04/24

$NAMS seriously, what could go wrong in phase 3?